不同类型冠心病患者血浆Hcy水平的变化

目的 探讨血浆同型半胱氨酸(Hcy)水平与冠心病(CHD)的关系.方法 将90例CHD患者分为两组,稳定型心绞痛组(SA)34例,急性冠脉综合征组(ACS)56例.另设对照组30名,为健康体检者.以分析法检测其空腹血浆Hcy水平.同时根据冠脉造影进一步将观察对象区分为单支病变组(31例)、双支病变组(29例)和多支病变组(30例).结果 CHD患者血浆Hcy水平显著高于对照组(P<0.01),ACS组显著高于SA组(P<0.05);多支病变组Hcy水平显著高于双支病变组(P<0.01),双支病变组高于单支病变组(P<0.05).结论 CHD患者血浆Hcy水平明显增高,且随冠状动脉病变程度及冠脉病变支数而增加,是CHD的危险因素之一.     

高浓度血浆血小板衍生生长因子C对冠心病患者冠状动脉病变的影响

目的探究血浆血小板衍生生长因子C(PDGF-C)浓度变化与冠心病及冠状动脉病变程度的关系。方法选择行冠状动脉造影住院的急性冠状动脉综合征(ACS)患者52例、稳定型心绞痛(SAP)患者52例,以及造影结果正常的其他患者为对照组50例。冠心病(ACS和SAP)患者中冠状动脉多支病变者60例,双支病变者25例,单支病变者19例。酶联免疫吸附试验(ELISA)法测定各组患者血浆PDGF-C浓度。比较各组间血浆PDGF-C浓度水平,并进行Spearman相关性分析、Logistic回归分析及绘制ROC曲线。结果 ACS组及SAP组血浆PDGF-C浓度比对照组高(P0.05)。冠状动脉多支及双支病变组血浆PDGF-C浓度比单支病变组高(P0.05)。Spearman相关性分析发现,血浆PDGF-C浓度与Gensini评分有一定相关性(r=0.218,P0.05)。Logistic回归分析发现,高浓度血浆PDGF-C相比于低浓度血浆PDGF-C,患者发生冠心病的风险增加(OR=1.006, 95%CI 1.002～1.011)。血浆PDGF-C浓度的ROC曲线下面积为0.645,灵敏度为77.88%。结论高浓度血浆PDGF-C可能是冠心病发病的危险因素,与冠状动脉病变的严重程度可能存在一定的关联。     

血浆血管性血友病因子水平与冠状动脉病变的关系

目的:测定血浆血管性血友病因子(vWF)浓度,探讨血浆vWF水平与冠状动脉病变之间的关系。方法:根据冠状动脉造影结果选择冠心病患者78例,分为单支病变组、双支病变组、多支病变组,测定其血浆vWF水平,并与冠状动脉病变积分作相关分析。同时选非冠心病患者29例作为正常对照组。结果:冠心病组血浆vWF水平较正常对照组血浆vWF水平明显升高,(181.24±26.56)%∶(157.11±26.63)%,P<0.01;多支病变组较单支病变组、双支病变组的血浆vWF水平明显升高,(195.52±26.57)%∶(165.24±26.90)%、(180.54±18.58)%,P分别<0.01、<0.05;双支病变组较单支病变组的血浆vWF水平也明显升高(P<0.05),对照组与单支病变组的血浆vWF水平无差异。血浆vWF水平与冠状动脉病变积分呈正相关(r=0.702,P<0.01)。结论:血浆vWF水平可较好反映冠心病患者血管内皮功能损伤程度和冠状动脉病变范围。     

血清氧化型低密度脂蛋白及同型半胱氨酸水平与冠状动脉病变严重程度的相关性研究

目的 通过观察血清氧化型低密度脂蛋白(OX-LDL)和同型半胱氨酸(Hcy)与冠心病(CHD)患者冠状动脉病变支数、稳定情况,以及血清OX-LDL与Hcy的相关性,探讨其对冠心病冠状动脉病变严重程度的预测价值.方法 选择冠状动脉造影确诊的CHD患者144例,其中不稳定型心绞痛(UAP)73例,稳定型心绞痛(SAP)71例,据冠脉造影结果 分为单支病变组(34例)、双支病变组(36例)和多支病变组(74例,≥3支病变),另选同期健康体检者50例为健康对照(NC)组.分析血清OX-LDL和Hcy与冠状动脉病变支数、稳定情况,以及血清OX-LDL与Hcy的相关性.结果 (1)UAP、SAP及NC组之间血清OX-LDL和Hcy水平差异有统计学意义(P＜0.01);UAP、SAP组血清OX-LDL和Hcy水平均显著高于NC组(P＜0.01);UAP与SAP组相比,血清OX-LDL和Hcy水平差异有统计学意义(P＜0.01).(2)CHD患者单支病变、双支病变及多支病变组血清OX-LDL和Hcy水平差异有统计学意义(P＜0.01),且随病变支数的增加而升高,多支病变组均显著高于双支病变组(P＜0.01),双支病变组显著高于单支病变组(P＜0.05,P＜0.01).(3)CHD患者血清OX-LDL与Hcy呈正相关(r=0.793,P＜0.01),病变支数与血清OX-LDL和Hcy呈显著正相关(r=0.625、0.719,均P＜0.01).结论 血清OX-LDL和Hcy水平与CHD冠状动脉病变、病变稳定性及病变支数有关,以及血清OX-LDL与Hcy具有相关一致性.联合检测血清OX-LDL和Hcy水平,可更好的了解病情、指导治疗及判断预后.     

冠心病患者血浆内脂素及基质金属蛋白酶-9的相关性及临床意义

目的探讨内脂素及基质金属蛋白酶-9(MMP-9)在冠心病(CHD)中的相关性及临床意义。方法选择80例经冠脉造影确诊为冠心病并排除糖尿病的患者和30名健康体检者。冠心病诊断标准为冠状动脉至少一支血管狭窄程度≥50%。将80例CHD患者分为急性冠脉综合征(ACS)组(50例)与稳定型心绞痛(SAP)组(30例)。根据冠脉造影将患者分为单支病变组(26例)、双支病变组(27例)、三支病变组(27例)。以酶联免疫吸附试验法检测80例患者及30例健康对照者血浆内脂素和MMP-9水平。结果 ACS与稳定型心绞痛患者血浆内脂素和MMP-9显著高于对照组(P<0.05),ACS患者血浆内脂素和MMP-9高于与稳定型心绞痛(P<0.05),三支病变组内脂素与MMP-9高于双支病变组(P<0.05),双支病变组高于单支病变组(P<0.05),单支病变组高于对照组(P<0.05)。内脂素水平与MMP-9水平显著正相关(r=-0.763,P<0.05)。结论内脂素、MMP-9与冠心病密切相关,且对冠心病的诊断及预测冠状动脉病变严重程度具有重要临床意义。     

血浆同型半胱氨酸与冠脉病变支数及冠心病不同类型的关系

目的探讨血浆同型半胱氨酸(homocysteine,Hcy)水平与冠状动脉病变支数及冠心病不同类型之间的关系。方法用高效液相色谱法对118例行选择性冠脉造影的患者进行血浆Hcy水平的测定。冠脉造影显示至少一支血管狭窄≥50%者为冠心病组(78例),血管狭窄<50%者诊为非冠心病组(40例)。冠心病患者进一步分为单支病变组(19例),双支病变组(27例),三支病变组(32例)。结果冠心病患者血浆Hcy水平显著高于非冠心病组(P<0.01),多支病变组血浆Hcy水平明显高于非冠心病组(P<0.01),单支病变组略高于非冠心病组(P<0.05),急性心肌梗死患者血浆Hcy水平明显高于非急性心肌梗死患者(P<0.01)。结论血浆Hcy水平升高是冠状动脉病变的危险因素,Hcy增高越显著,则冠脉病变支数越多。Hcy水平升高与冠状动脉的急性病变有关。     

冠心病病人non-HDL-C、D-D、Fg、EPCs的变化及其与病情的关系

目的探讨非高密度脂蛋白胆固醇(non-HDL-C)、D-二聚体(D-D)、纤维蛋白原(Fg)、循环内皮祖细胞(EPCs)在冠心病病人中的变化及其意义。方法选取2015年1月—2017年10月确诊的冠心病病人200例作为CHD组,其中稳定型心绞痛(SAP)病人90例、不稳定型心绞痛(UAP)病人70例、急性心肌梗死(AMI)病人40例;单支冠状动脉狭窄90例,双支冠状动脉狭窄72例,三支冠状动脉狭窄38例。另选取健康者100名为对照组。对比CHD组与对照组non-HDL-C、D-D、Fg、EPCs水平,并根据冠心病类型、冠状动脉病变支数进行分层分析。结果 CHD组non-HDL-C、D-D、Fg水平均高于对照组(P 0.05),EPCs水平低于对照组(P 0.05);AMI组non-HDL-C、D-D、Fg水平高于SAP组(P 0.05),UAP组与AMI组EPCs水平低于SAP组(P 0.05);AMI组non-HDL-C、D-D、Fg水平均高于UAP组(P 0.05),AMI组EPCs水平低于UAP组(P 0.05);双支冠状动脉病变组、三支冠状动脉病变组non-HDL-C、D-D、Fg水平均高于单支冠状动脉病变组(P 0.05),双支冠状动脉病变组、三支冠状动脉病变组EPCs水平均低于单支冠状动脉病变组(P 0.05);三支冠状动脉病变组non-HDL-C、D-D、Fg水平均高于双支冠状动脉病变组(P 0.05),三支冠状动脉病变组EPCs水平低于双支冠状动脉病变组(P 0.05)。结论冠心病病人的non-HDL-C、D-D、Fg水平均升高,EPCs水平降低,并且与冠状动脉病变程度、冠心病病情变化有关。     

冠心病患者血浆纤维蛋白原、D-二聚体(D-D)水平检测

目的探讨冠心病患者血浆纤维蛋白原(Fg)、D-二聚体(D-D)的变化。方法 116例CHD患者其中单支血管病变组39例,双支血管病变组46例,多支血管病变组31例;不稳定性心绞痛(UAP)44例,急性心肌梗死(AMI)37例,稳定性心绞痛(SAP)35例与对照组77例,采集静脉血,检测血浆Fg、D-D水平,然后进行统计学处理。结果冠心病患者血浆Fg、D-D含量较非冠心病者明显升高(P0.01);且与冠脉病变程度及类型相关,3支病变者血浆Fg、D-D高于2支和单支病变者(P0.01)。急性心肌梗死(AMI)和不稳定型心绞痛(UAP)组血浆Fg、D-D水平较稳定型心绞痛(SAP)组及非冠心病组明显升高(P0.01)。结论血浆Fg、D-D水平与冠心病的发病及病变程度密切相关。对预测心血管事件和判断冠脉病变严重程度有参考价值。     

血栓调节蛋白含量与冠状动脉病变的关系

目的测定血浆血栓调节蛋白(Thrombomodulin,TM)含量,并探讨血浆TM的值与冠状动脉病变之间的关系。方法根据冠状动脉造影将观察对象分为4组:正常对照组、单支病变组、双支病变组、多支病变组。经股动脉穿刺抽取血液,用酶联免疫吸附试验测量其血浆TM值。结果多支病变组TM水平明显高于正常对照组、单支病变组及双支病变组(P<0.01),单支病变组及双支病变组TM水平明显高于正常对照组(P<0.05),单支病变组与双支病变组之间无显著性差异(P>0.078)。结论血浆血栓调节蛋白的水平相对好的反映冠心病患者内皮细胞损伤程度和冠脉病变范围。     

冠心病患者血浆IL-6及内脂素水平与冠状动脉病变严重程度相关性研究

目的 分析冠心病患者血浆白介素（IL）-6和内脂素水平与冠状动脉病变严重程度的相关性。方法 选择经冠状动脉造影确诊的冠心病患者128例,分为急性冠脉综合征（ACS）组和稳定型心绞痛（SAP）组,并按病变血管支数分成3组（单支病变组、双支病变组和三支病变组）,按冠状动脉狭窄程度分为3组（冠状动脉狭窄程度50%~75%组、76%~90%组及91%~100%组）。收集患者的基本临床资料,血浆IL-6及内脂素应用酶联免疫吸附法测定,应用Gensini积分评价冠状动脉病变严重程度。结果 ACS组患者IL-6及内脂素水平显著高于SAP组（P<0.05）,按照不同病变血管支数分组和按照病变血管狭窄程度分组后,血浆IL-6及内脂素水平在各组间差异具有显著性（P<0.05）。相关分析显示IL-6、内脂素与Gensini积分呈正相关（分别r=0.583,r=0.724,均P<0.01）。结论 IL-6及内脂素与冠状动脉病变严重程度密切相关。     

联合检测氨基末端脑钠肽前体和高敏C反应蛋白与冠脉病变程度的相关性研究

目的探讨急性冠脉综合征(ACS)患者冠状动脉粥样硬化程度和血浆氨基末端脑钠肽前体、高敏C反应蛋白水平之间的相关性。方法 ACS患者120例均行冠状动脉造影术,分为不稳定型心绞痛组(UAP组)40例,急性非ST段抬高性心肌梗死组(NSTEMI组)40例与急性ST段抬高性心肌梗死组(STEMI组)40例;同期正常体检者40名作为对照组。冠状动脉病变严重程度用病变血管支数及Gensini评分表示,于入院第2天抽血检测血浆氨基末端脑钠肽前体和高敏C反应蛋白水平,并进行比较。结果 ACS各组血浆氨基末端脑钠肽前体、高敏C反应蛋白水平和Gensini评分显著高于对照组(P<0.01),ACS各组氨基末端脑钠肽前体水平比较差异有统计学意义(P<0.05),Gensini评分各组比较差异无统计学意义;STEMI组高敏C反应蛋白水平高于NSTEMI组和UAP组(P<0.01);NSTEMI组与UAP组高敏C反应蛋白水平比较差异无统计学意义。血浆氨基末端脑钠肽前体、高敏C反应蛋白水平和Gensini评分随病变支数的增加而增加。结论联合检测氨基末端脑钠肽前体和高敏C反应蛋白水平可判断ACS的严重程度,对其诊治及指导早期行有创检查均有重要参考价值。     

急性冠状动脉综合征病人治疗前后血浆脑钠肽N末端前体水平

目的观察急性冠状动脉综合征病人血浆脑钠肽N末端前体（N-terminal pro—brain natrluretic peptide,NT—proBNP）水平变化,评价该指标在急性冠状动脉综合征病人治疗中的临床意义。方法急性冠状动脉综合征病人60例（冠心病急性心肌梗死29例,不稳定型心绞痛31例）,稳定性心绞痛33例,正常对照28例。采用电化学发光双抗体夹心免疫法分析检测血浆NT—proBNP水平,以超声心动图评价心功能．同时对急性心肌梗死25例经皮冠状动脉介入术前后上述指标进行分析。结果急性冠状动脉综合征组病人血浆NT-proBNP水平为3630ng／L（95％可信区间1412～9332）,明显高于对照组75．8ng／L（95％可信区间40～144）（P〈0．001）,而稳定性心绞痛组与对照组之间差异无统计学差异（P〉0．05）。且25例急性冠状动脉综合征病人在经皮冠状动脉介人术后12～24小时内血浆NT—proBNP水平从术前4732ng／L（95％可信区间为1828～12246）降至344ng／L（95％可信区间为192～616）,差异有统计学意义（P〈0．01）。结论急性冠状动脉综合征病人血浆NT-proBNP含量明显升高,提示NT—proBNP可作为早期评估急性冠状动脉综合征病人的心功能情况。治疗后含量明显降低,可作为观察疗效的一个指标。     

血浆脂联素在冠心病患者中的变化及其临床意义

目的:观察冠心病患者血浆脂联素(APN)水平,及血浆APN水平与急性冠状动脉综合征(ACS)之间的关系。方法:经冠状动脉造影证实的冠心病患者共110例,其中稳定型心绞痛组35例,不稳定型心绞痛组42组,急性心肌梗死组33例,并且选取20例正常健康人作为对照组。采用ELISA法检测血浆APN水平,同时检测各组生化指标,如空腹血糖、TC、TG、LDL-C、HDL-C等。结果:急性心肌梗死组、不稳定型心绞痛组中血浆APN浓度显著低于稳定型心绞痛以及对照组。logistic多元逐步分析显示吸烟、空腹血糖以及低血浆APN浓度与ACS发生独立相关。结论:血浆APN可能是评估冠心病的新的独立危险因素,可能与ACS的发生有关。     

Comparison between metalloproteinases-2 and -9 in healthy subjects,diabetics, and subjects with acute coronary syndrome

We hypothesized that matrix metalloproteinase (MMP)-2, -9, and tissue inhibitor metalloproteinase-1, -2 (TIMP-1, -2) would be abnormal in diabetes and in acute coronary syndromes (ACS). We measured MMP-2, -9, and TIMP-1, -2 plasma levels in healthy subjects (controls), in type 2 diabetic patients, in nondiabetic patients with ACS (ACS) and in diabetic patients with ACS (DACS). We enrolled 165 controls, 181 diabetic patients, 78 ACS, and 46 DACS. We measured also BMI (body mass index), HbA_1c (glycated hemoglobin) FPG (fasting plasma glucosa), FPI (fasting plasma insulin), HOMA index (homeostasis model assessment index), SBP (systolic blood pressure), DBP (diastolic blood pressure), TC (total cholesterol), LDL-C (low density lipoprotein cholesterol), HDL-C (high-density lipoprotein cholesterol), Tg (triglycerides), Lp(a) (lipoprotein(a)) PAI-1 (plasminogen activator inhibitor-1), Hct (homocysteine), Fg (fibrinogen), and hs-CRP (high-sensitivity C-reactive protein). A significant increase of BMI was observed in the diabetic group, in ACS and DACS patients compared to controls. A significant increase of SBP and DBP resulted in the diabetic and DACS groups, while only SBP improvement was present in ACS patients with respect to controls. A decrease in SBP and DBP was observed in the ACS group, while SBP variation was present in DACS patients compared to diabetics, and DBP increase was obtained in the DACS group with respect to ACS patients. TC, LDL-C, Tg, and Lp(a) increase was present in diabetics, while TC, Tg, and Lp(a) improvement was present in ACS and DACS patients with a significant decrease of HDL-C levels in diabetic, ACS, and DACS groups compared to controls. A decrease in LDL-C was obtained in ACS and DACS groups, while HDL-C increase was observed in these patients with respect to diabetics. Tg levels were higher in the DACS group compared to diabetics and ACS patients, respectively. Increases in PAI-1, Hct, Fg, and hs-CRP were present in diabetic and DACS groups, while PAI-1, Hct, and hs-CRP improvement was obtained in ACS patients with respect to controls. Higher PAI-1 levels came about in ACS and DACS groups, while HCT and Fg levels were lower in ACS patients compared to diabetics. An increase in Fg was present in the DACS group with respect to ACS patients. A decrease in Hs-CRP was observed in DACS patients compared to diabetics and the ACS group, respectively. Higher MMP-2, MMP-9, TIMP-1, and TIMP-2 levels were present in diabetic, ACS, and DACS patients compared to controls. Significant MMP-2, TIMP-1, and TIMP-2 increases were observed in ACS and DACS groups, while MMP-9 decreased in these patients compared to diabetics. In conclusion, MMP-2, MMP-9, TIMP-1, and TIMP-2 plasma levels were higher in diabetic, ACS, and DACS patients, which may reflect abnormal extracellular matrix metabolism in diabetes and in acute coronary syndrome.     

Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes.

BACKGROUND AND OBJECTIVES: Unfractionated heparin (UFH) and enoxaparin (low molecular weight heparin) constitute fundamental therapies in the treatment of patients with acute coronary syndrome (ACS). Since enoxaparin appears to offer clinical advantages over UFH in managing ACS, markers of thrombin generation, endothelial function and acute phase response could manifest different responses to UFH or enoxaparin. The purpose of the present study was to investigate the effect that treatment with either UFH or enoxaparin has on plasma hemostatic markers in 24 patients with ACS. DESIGN AND METHODS: The patients were randomized to receive 5,000 IU intravenous bolus and continuous infusion of 18 IU/Kg/h UFH (n=11) or 1 mg/kg/12h subcutaneous enoxaparin (n=13). The plasma levels of fibrinogen (Fg), prothrombin fragment 1+2 (F1+2), thrombin antithrombin complex (TAT), von Willebrand factor (vWF), tissue factor (TF) and tissue factor pathway inhibitor (TFPI) were assayed at admission and 6, 12, 24 and 48 hours after heparin treatment. RESULTS: Upon admission, UFH and enoxaparin patients showed a significant increase in all the hemostatic parameters measured with respect to the levels in the control subjects. In comparison with the baseline levels of the UFH- and enoxaparin-treated patients, Fg showed a significant increase at 48 h and TFPI at 6, 12 and 24 hours. However, at 48 hours TFPI levels were not significantly higher than the basal values. There were no significant changes in F1+2, TAT, vWF or TF. INTERPRETATION AND CONCLUSIONS: Markers of thrombin generation, endothelial function and acute-phase reactants manifest a similar response to UFH and enoxaparin. An increase in thrombin generation may be a result of persistently activated inflammatory and endothelial processes, despite UFH and enoxaparin treatment.     

奥扎格雷对急性冠状动脉综合征患者P-选择素的影响

目的:观察奥扎格雷对急性冠状动脉综合征(ACS)患者P-选择素水平的影响。方法:选择80例ACS患者,其中急性心肌梗死(AMI)40例,不稳定型心绞痛(UAP)40例;随机分为治疗组(标准治疗加奥扎格雷,40例)和对照组(标准治疗,40例),分别测定治疗前后患者血浆P-选择素浓度,进行统计学分析。结果:2组患者治疗前的血浆P-选择素浓度明显增高,治疗后均有下降,治疗组P-选择素下降幅度(54%)大于对照组(28%)。结论:用奥扎格雷治疗ACS患者,能显著降低血浆P-选择素的浓度。     

急性冠脉综合征患者血浆P-选择素及血清一氧化氮水平相关性研究

目的观察血浆P-选择素(P-selectin)及血清一氧化氮(NO)水平在急性冠脉综合征(ACS)患者中的变化,探讨其与急性冠脉综合征的关系。方法用ELISA方法测定60例急性冠脉综合征患者-急性心肌梗死(AMI)、不稳定型心绞痛(UAP)各30例,30例稳定型心绞痛患者(SAP)、30例体检健康者血浆P-selectin及血清NO水平。结果⑴急性冠脉综合征患者血浆P-selectin水平较稳定型心绞痛患者及健康对照组明显升高(P<0.01),⑵急性冠脉综合征患者血清NO水平较对照组明显降低(P<0.01)。⑶血清NO与血浆P-selectin水平成负相关(P<0.01),与高密度脂蛋白胆固醇(HDL-C)水平成正相关(P<0.05)。结论血浆P-selectin及血清NO水平对急性冠脉综合征的诊断有指导意义。     

急性冠脉综合征血管内超声斑块显像与血清淀粉样蛋白A、妊娠相关蛋白A表达的相关性研究

目的：探讨急性冠脉综合征（ACS）患者血管内超声（IVUS）显像与血清淀粉样蛋白A（SAA）、妊娠相关血浆蛋白A（PAPP-A）浓度的相关性。方法：按照1979年WHO缺血性心脏病诊断标准选择80例住院冠心病患者,分为稳定型心绞痛（SAP）组（20例）和ACS组（60例）,所有患者均行IVUS、冠脉造影检查,术前至少1h分别检测患者血清SAA、血浆PAPP-A的浓度,并与IVUS检查所得出的斑块纤维帽厚度、偏心指数、重构指数比较,分析其相关性。结果：与SAP组患者相比,ACS组患者纤维帽厚度明显变薄[（1.0±0.2）mm∶（0.7±0.1）mm],偏心指数[（0.4±0.1）∶（0.9±0.2）]、重构指数明显提高[（0.8±0.1）∶（1.3±0.2）],SAA[（13.75±9.65）MIU/L∶（36.4±12.32）MIU/L]、PAPP-A[（10.36±8.25）mg/L∶（32.68±12.5）mg/L]浓度明显升高（P均〈0.001）。SAA、PAPP-A水平与纤维帽厚度均呈负相关（r=-0.68,-0.68,P均〈0.05）,与偏心指数（r=0.75,0.81）、重构指数（r=0.71,0.78）呈正相关（P均〈0.05）。结论：急性冠脉综合征患者易损斑块的纤维帽厚度、偏心指数、重构指数（斑块稳定性）与血清淀粉样蛋白A、妊娠相关蛋白A存在相关关系,血清淀粉样蛋白A、妊娠相关蛋白A可作为预测易损斑块稳定性的重要指标。     

急性冠状动脉综合征患者血浆组织因子和白细胞介素18水平的变化及意义

目的观察急性冠状动脉综合征(ACS)患者血浆组织因子和白细胞介素18水平的变化及其关系,探讨凝血与炎症的相关性及其在ACS发生、发展中的作用。方法选择冠心病患者118例,根据诊断分为ACS组67例和稳定性心绞痛组51例,2组患者测定血浆组织因子和白细胞介素18水平,并进行比较,采用Pearson相关分析法分析两变量的相关性。结果 ACS组血浆组织因子和白细胞介素18水平明显高于稳定性心绞痛组[(101.44±21.32)ng/L vs(90.01±19.44)ng/L,(311.73±113.00)ng/L vs(246.59±94.63)ng/L,P<0.01];ACS组血浆组织因子与白细胞介素18呈正相关(r=0.654,P<0.01),稳定性心绞痛组血浆组织因子与白细胞介素18无相关性(P>0.05)。结论 ACS患者体内炎症活动与凝血活动可能互相作用。     

Decrease in plasma adiponectin concentrations in patients with variant angina pectoris.

BACKGROUND: Plasma adiponectin is decreased in patients with coronary artery diseases, especially in patients with acute coronary syndrome (ACS). However, the correlation between plasma adiponectin and variant angina pectoris (VAP) has not been verified. Plasma adiponectin concentrations between VAP and other coronary artery diseases was compared in the present study. The association between plasma adiponectin concentration and VAP was also investigated. METHODS AND RESULTS: Plasma adiponectin concentrations in the VAP group (n=101) were compared with those of the ACS group (n=117), the stable angina pectoris group (n=108), and the normal coronary group (n=81). Plasma adiponectin concentrations in VAP and ACS were significantly lower than that of the normal coronary group (6.6+/-5.4 vs 5.2+/-4.0 vs 9.0 +/-6.2 microg/ml, p<0.001, respectively). Multivariate analysis indicated that plasma adiponectin (odds ratio (OR) 0.735, 95% confidence interval (CI) 0.621-0.855, p=0.011), smoking (OR 2.012, 95% CI 1.210-3.880, p=0.020), and age (OR 0.976, 95% CI 0.957-0.997, p=0.022) correlated independently with the development of VAP. CONCLUSIONS: Our results suggest that a decrease in plasma adiponectin concentration might be associated with the development of VAP.